Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics (Nasdaq: ANTX) reported that four abstracts featuring clinical and nonclinical data on epetraborole, a boron-containing oral candidate for polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, held September 9‑12, 2026, in Houston, Texas.
According to AN2 Therapeutics, the abstracts describe potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters, along with hematological and safety data across healthy volunteers, non-PV patients, and nonhuman primate models. Exposure‑response relationships observed in nonhuman primates were reported to predict effects later seen in humans, supporting the translational value of these models and the ongoing clinical development of epetraborole as a potential oral PV treatment.
AN2 Therapeutics (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as Chief Medical Officer, adding more than 20 years of clinical, translational and drug development leadership experience across hematology, rare diseases, oncology, immunology and metabolic disorders. According to AN2 Therapeutics, Dr. Trenor has led programs from discovery through global clinical development, regulatory interactions and commercialization planning.
He previously served as CMO of Cellarity, overseeing its first IND and global first-in-human study, and as Executive Medical Director at Forma Therapeutics, where he led development of etavopivat into Phase 3. Co-founder George H. Talbot, M.D., who led AN2’s clinical programs over the last two years, will continue as senior scientific advisor and strategic advisor during the transition.
AN2 Therapeutics (Nasdaq: ANTX) reported Q2 2026 R&D expenses of $6.0 million and G&A expenses of $2.9 million, leading to a net loss of $8.2 million. Cash, cash equivalents and investments totaled $79.9 million, which the company projects will fund operations into 2029.
AN2 is advancing three Phase 2 programs: a global proof-of-concept trial of oral epetraborole in polycythemia vera with IND filing expected in Q3 2026 and enrollment in Q4 2026; an ongoing 84-patient investigator-initiated Phase 2 trial of epetraborole in M. abscessus lung disease with topline data anticipated in late 2027; and a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease planned for late 2026, supported by 100% parasitic elimination in a non-human primate study and a generally well-tolerated Phase 1 profile.
The company also declared an ENPP1 development candidate for solid tumors and expects to advance a second boron-based oncology candidate by year-end 2026.
AN2 Therapeutics (Nasdaq: ANTX) reported enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. In nonhuman primates with naturally acquired chronic T. cruzi infection, 28 days of treatment achieved 100% parasite elimination, durable to four months. A Phase 1 study showed AN2-502998 was generally well tolerated with no dose-limiting toxicities and human exposures meeting nonhuman primate efficacy thresholds, supporting advancement to a planned Phase 2 proof-of-concept trial and highlighting a potential multi-billion-dollar U.S. and global commercial opportunity, including possible FDA Tropical Disease Priority Review Voucher eligibility if approved.
AN2 Therapeutics (Nasdaq: ANTX) announced that Co-Founder, Chairman, President and CEO Eric Easom will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET.
Management will also host 1x1 meetings, and a webcast and 30-day replay will be available via the investor relations website.
AN2 Therapeutics (Nasdaq: ANTX) reported first quarter 2026 results and multiple clinical milestones. R&D expenses were $6.7 million, G&A $3.8 million, and net loss $10.0 million. Cash, cash equivalents and investments totaled $85.3 million, including $40.0 million in March 2026 private placement proceeds.
The company advanced oral epetraborole toward a Phase 2 trial in polycythemia vera, supported a Phase 2 investigator-initiated trial in M. abscessus lung disease, progressed AN2-502998 for chronic Chagas disease, and declared an ENPP1 candidate for solid tumors. AN2 projects cash runway into 2029.
AN2 Therapeutics (Nasdaq: ANTX) announced management will participate at the 2026 Stifel Virtual Targeted Oncology Forum. Eric Easom, co-founder and CEO, will appear in a fireside chat on May 19, 2026 at 4:00 PM ET, and management is available for 1x1 meetings. A live webcast and an archived replay (available for at least 30 days) will be accessible on the company's Investors website.
AN2 Therapeutics (Nasdaq: ANTX) announced initiation of a Phase 2 investigator-initiated trial of epetraborole for Mycobacterium abscessus lung disease. The 84-patient, multicenter, randomized, double-blind study is led by Dr. Kevin Winthrop at OHSU across an estimated 10–15 U.S. sites.
Patient screening is underway and topline data are planned for late 2027. Epetraborole is an oral inhibitor of leucyl-tRNA synthetase being evaluated for safety, efficacy, and pharmacokinetics.
AN2 Therapeutics (Nasdaq: ANTX) reported Q4 and full-year 2025 results and program updates. Key clinical milestones include planned Phase 2 for oral epetraborole in polycythemia vera starting 3Q26 with data possible from 4Q26, an FDA-cleared Phase 2 investigator-initiated trial in M. abscessus (enrollment 1Q26, topline late 2027), and nearing Phase 1 readout for AN2-502998 in Chagas (initial data expected 1Q26). The company plans two oncology candidates in 2026 and completed a ~$40M private placement, projecting runway into 2029.
AN2 Therapeutics (Nasdaq: ANTX) entered a securities purchase agreement for a private placement expected to raise approximately $40 million gross, before placement agent fees and expenses. The company will sell 8,245,611 common shares at $2.85 each and offer pre-funded warrants for up to 5,789,493 shares at $2.84999 each.
The pre-funded warrants carry a $0.00001 exercise price and are exercisable immediately subject to ownership limits. The offering is expected to close on March 10, 2026, subject to customary conditions, and AN2 will file a registration statement to register resale of the securities.